Data from A Blood-Based Assay for Detection of Patients with Advanced Adenomas

Data from Detection of Cancers Three Years prior to Diagnosis Using Plasma Cell-Free DNA

Data from Detection of Human Brain Cancers using Genomic and Immune Cell Characterization of Cerebrospinal Fluid through CSF-BAM

Data from The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer

Data from The origin of highly elevated cell-free DNA in healthy individuals and patients with pancreatic, colorectal, lung, or ovarian cancer

Data from The origin of highly elevated cell-free DNA in healthy individuals and patients with pancreatic, colorectal, lung, or ovarian cancer

Figure 1 from A Blood-Based Assay for Detection of Patients with Advanced Adenomas

Figure 2 from A Blood-Based Assay for Detection of Patients with Advanced Adenomas

Figure 3 from A Blood-Based Assay for Detection of Patients with Advanced Adenomas

Figure 4 from A Blood-Based Assay for Detection of Patients with Advanced Adenomas

Figure S1 from A Blood-Based Assay for Detection of Patients with Advanced Adenomas

Figure S1 from A Blood-Based Assay for Detection of Patients with Advanced Adenomas

Figure S1 from The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer

Figure S1 from The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer

Figure S1 from The origin of highly elevated cell-free DNA in healthy individuals and patients with pancreatic, colorectal, lung, or ovarian cancer

Figure S1 from The origin of highly elevated cell-free DNA in healthy individuals and patients with pancreatic, colorectal, lung, or ovarian cancer

Figure S10 from The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer

Figure S10 from The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer

Figure S10 from The origin of highly elevated cell-free DNA in healthy individuals and patients with pancreatic, colorectal, lung, or ovarian cancer

Figure S10 from The origin of highly elevated cell-free DNA in healthy individuals and patients with pancreatic, colorectal, lung, or ovarian cancer

Figure S2 from A Blood-Based Assay for Detection of Patients with Advanced Adenomas

Figure S2 from A Blood-Based Assay for Detection of Patients with Advanced Adenomas

Figure S2 from The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer

Figure S2 from The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer

Figure S2 from The origin of highly elevated cell-free DNA in healthy individuals and patients with pancreatic, colorectal, lung, or ovarian cancer

Figure S2 from The origin of highly elevated cell-free DNA in healthy individuals and patients with pancreatic, colorectal, lung, or ovarian cancer

Figure S3 from A Blood-Based Assay for Detection of Patients with Advanced Adenomas

Figure S3 from A Blood-Based Assay for Detection of Patients with Advanced Adenomas

Figure S3 from The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer

Figure S3 from The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer

Figure S3 from The origin of highly elevated cell-free DNA in healthy individuals and patients with pancreatic, colorectal, lung, or ovarian cancer

Figure S3 from The origin of highly elevated cell-free DNA in healthy individuals and patients with pancreatic, colorectal, lung, or ovarian cancer

Figure S4 from A Blood-Based Assay for Detection of Patients with Advanced Adenomas

Figure S4 from A Blood-Based Assay for Detection of Patients with Advanced Adenomas

Figure S4 from The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer

Figure S4 from The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer

Figure S4 from The origin of highly elevated cell-free DNA in healthy individuals and patients with pancreatic, colorectal, lung, or ovarian cancer

Figure S4 from The origin of highly elevated cell-free DNA in healthy individuals and patients with pancreatic, colorectal, lung, or ovarian cancer

Figure S5 from A Blood-Based Assay for Detection of Patients with Advanced Adenomas

Figure S5 from A Blood-Based Assay for Detection of Patients with Advanced Adenomas

Figure S5 from The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer

Figure S5 from The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer

Figure S5 from The origin of highly elevated cell-free DNA in healthy individuals and patients with pancreatic, colorectal, lung, or ovarian cancer

Figure S5 from The origin of highly elevated cell-free DNA in healthy individuals and patients with pancreatic, colorectal, lung, or ovarian cancer

Figure S6 from The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer

Figure S6 from The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer

Figure S6 from The origin of highly elevated cell-free DNA in healthy individuals and patients with pancreatic, colorectal, lung, or ovarian cancer

Figure S6 from The origin of highly elevated cell-free DNA in healthy individuals and patients with pancreatic, colorectal, lung, or ovarian cancer

Figure S7 from The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer

Figure S7 from The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer

Figure S7 from The origin of highly elevated cell-free DNA in healthy individuals and patients with pancreatic, colorectal, lung, or ovarian cancer

Figure S7 from The origin of highly elevated cell-free DNA in healthy individuals and patients with pancreatic, colorectal, lung, or ovarian cancer

Figure S8 from The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer

Figure S8 from The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer

Figure S8 from The origin of highly elevated cell-free DNA in healthy individuals and patients with pancreatic, colorectal, lung, or ovarian cancer

Figure S8 from The origin of highly elevated cell-free DNA in healthy individuals and patients with pancreatic, colorectal, lung, or ovarian cancer

Figure S9 from The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer

Figure S9 from The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer

Figure S9 from The origin of highly elevated cell-free DNA in healthy individuals and patients with pancreatic, colorectal, lung, or ovarian cancer

Figure S9 from The origin of highly elevated cell-free DNA in healthy individuals and patients with pancreatic, colorectal, lung, or ovarian cancer

Supplemental Table 1 from A Blood-Based Assay for Detection of Patients with Advanced Adenomas

Supplemental Table 1 from A Blood-Based Assay for Detection of Patients with Advanced Adenomas

Supplemental Table 2 from A Blood-Based Assay for Detection of Patients with Advanced Adenomas

Supplemental Table 2 from A Blood-Based Assay for Detection of Patients with Advanced Adenomas

Supplemental Table 3 from A Blood-Based Assay for Detection of Patients with Advanced Adenomas

Supplemental Table 3 from A Blood-Based Assay for Detection of Patients with Advanced Adenomas

Supplemental Table 4 from A Blood-Based Assay for Detection of Patients with Advanced Adenomas

Supplemental Table 4 from A Blood-Based Assay for Detection of Patients with Advanced Adenomas

Supplementary Data from A Blood-Based Assay for Detection of Patients with Advanced Adenomas

Supplementary Data from A Blood-Based Assay for Detection of Patients with Advanced Adenomas

Supplementary Data from A Blood-Based Assay for Detection of Patients with Advanced Adenomas

Supplementary Data from A Blood-Based Assay for Detection of Patients with Advanced Adenomas

Supplementary Figures S1-S9 from Detection of Human Brain Cancers using Genomic and Immune Cell Characterization of Cerebrospinal Fluid through CSF-BAM

Supplementary Notes 1-5 from The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer

Supplementary Notes 1-5 from The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer

Supplementary Notes 1-5 from The origin of highly elevated cell-free DNA in healthy individuals and patients with pancreatic, colorectal, lung, or ovarian cancer

Supplementary Notes 1-5 from The origin of highly elevated cell-free DNA in healthy individuals and patients with pancreatic, colorectal, lung, or ovarian cancer

Supplementary Tables S1 and S2 from The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer

Supplementary Tables S1 and S2 from The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer

Supplementary Tables S1 and S2 from The origin of highly elevated cell-free DNA in healthy individuals and patients with pancreatic, colorectal, lung, or ovarian cancer

Supplementary Tables S1 and S2 from The origin of highly elevated cell-free DNA in healthy individuals and patients with pancreatic, colorectal, lung, or ovarian cancer

Supplementary Tables S1 to S6 from Detection of Cancers Three Years prior to Diagnosis Using Plasma Cell-Free DNA

Supplementary Tables S1-S19 from Detection of Human Brain Cancers using Genomic and Immune Cell Characterization of Cerebrospinal Fluid through CSF-BAM

Table 1 from A Blood-Based Assay for Detection of Patients with Advanced Adenomas

Table 2 from A Blood-Based Assay for Detection of Patients with Advanced Adenomas

Table 3 from A Blood-Based Assay for Detection of Patients with Advanced Adenomas

supplemental table 5 from A Blood-Based Assay for Detection of Patients with Advanced Adenomas

supplemental table 5 from A Blood-Based Assay for Detection of Patients with Advanced Adenomas